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ABSTACT  26 
 27 
Purpose: To measure corneal riboflavin penetration using different 28 
transepithelial iontophoresis protocols. 29 
 30 
Methods: Freshly enucleated rabbit eyes were divided into 9 treatment groups 31 
of 4 eyes. One group, in which 0.1% w/v riboflavin was applied for 30 minutes 32 
without iontophoresis after corneal epithelial debridement, acted as a control. 33 
The remaining groups were treated with an intact epithelium using different 34 
riboflavin formulations and varying iontophoresis current, soak and rinse 35 
times.  After riboflavin application, eyes were snap frozen in liquid nitrogen. 36 
Thirty-five µm thick corneal cross-sections were then imaged immediately by 37 
two-photon fluorescence microscopy, using image processing software to 38 
quantify stromal riboflavin concentration at different corneal depths.  39 
 40 
Results: In the epithelium-on iontophoresis treatment groups, greater stromal 41 
riboflavin penetration was achieved with higher concentration riboflavin 42 
solutions, greater iontophoresis dosage and longer solution contact times. A 43 
protocol utilizing 0.25 % w/v riboflavin with benzalkonium chloride (BAC) 0.01 44 
% and two cycles of applied current and subsequent soaking (1 mA 5 45 
minutes, soak 5 minutes, 0.5 mA 5 minutes, soak 5 minutes) achieved similar 46 
stromal riboflavin penetration to epithelium-off controls. The best performing 47 
non-BAC containing protocol produced stromal riboflavin penetration 48 
approximately 60% that of epithelium-off controls. Riboflavin solutions 49 
containing saline resulted in minimal stromal penetration. Riboflavin loading 50 
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within the epithelium was equivalent to, or higher than that in the subjacent 51 
stroma, despite rinsing the ocular surface with balanced salt solution.   52 
 53 
Conclusion: Modified iontophoresis protocols can significantly improve 54 
transepithelial riboflavin penetration in experimental corneal collagen cross-55 
linking. 56 
 57 
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INTRODUCTION 74 
 75 
Riboflavin/Ultraviolet A corneal collagen cross-linking (CXL), is the first 76 
intervention shown to halt disease progression in keratoconus.1–4 Riboflavin 77 
acts as a photo-sensitizer for the production of free radicals that drive the 78 
cross-linking process.5 Whilst riboflavin is hydrophilic with a molecular weight 79 
of 340 Dalton (Da), the corneal epithelium is lipophilic and has a reduced 80 
permeability to molecules larger than 180 Da.6,7 Thus standard CXL requires 81 
debridement of the central of epithelium to facilitate stromal riboflavin 82 
penetration and achieve adequate efficacy.7 Epithelial debridement, however, 83 
is associated with post-operative pain, delayed visual recovery and increases 84 
the risks of infection, corneal melt and scarring.8 As a result, CXL is normally 85 
reserved for patients with documented disease progression. 86 
 87 
Transepithelial (epithelium-on) CXL aims to avoid the pain, delayed recovery 88 
and complications of epithelial removal inherent in epithelium-off CXL. The 89 
original dextran-containing solutions have been shown in both laboratory and 90 
clinical studies to be ineffective for transepithelial cross-linking.9–12 A number 91 
of formulations of riboflavin designed to facilitate penetration across an intact 92 
corneal epithelium are currently marketed.13 Most contain toxic agents to 93 
increase epithelial permeability, including benzalkonium chloride (BAC), high 94 
concentration sodium chloride, sodium ethylenediaminetetraacetic acid 95 
(EDTA) or trometamol. Despite these chemical enhancers, results in clinical 96 
studies with transepithelial riboflavin preparations have been equivocal: some 97 
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studies report similar efficacy to epithelium-off CXL,14,15 but most report 98 
inferior results.10–12,16–18 99 
 100 
Iontophoresis, in which an electrical gradient is used to drive negatively-101 
charged riboflavin molecules across the intact epithelium, may further 102 
enhance riboflavin penetration in transepithelial CXL. Laboratory studies of 103 
iontophoresis have been encouraging, demonstrating enhanced 104 
transepithelial riboflavin penetration and improvement of corneal 105 
biomechanics.19–23 Initial clinical studies report improvements in keratometric 106 
and visual parameters.24–26 107 
 108 
We have previously investigated transepithelial stromal riboflavin penetration 109 
of commercially-available protocols in an ex vivo rabbit eye model using two-110 
photon fluorescence (TPF) microscopy, and have found that none are able to 111 
match the stromal riboflavin concentrations achieved epithelium-off.13 Here, 112 
using the same method, we investigate whether modified iontophoresis 113 
protocols designed by one of the authors (DO’B) can enhance riboflavin 114 
penetration across an intact epithelium. 115 
 116 
 117 
 118 
 119 
 120 
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METHODS 121 
 122 
Ethical approval for corneal TPF microscopy studies in an ex vivo model was 123 
granted by University College London Institute of Ophthalmology (ref. 124 
10/H0106/57-2012ETR27). 125 
 126 
Sample preparation 127 
Adult pigmented rabbit heads transported on ice in a phosphate buffered 128 
saline (PBS) bath were received within 5 hours post-mortem (First Link Ltd., 129 
Wolverhampton, UK) to minimise epithelial cell layer degeneration following 130 
death. Intact globes were enucleated and examined under a low-magnification 131 
light microscope to rule out obvious epithelial trauma or scars. The globes 132 
were warmed to room temperature in PBS before the iontophoresis system 133 
was set up.  134 
 135 
The iontophoresis system comprised 2 electrodes: a negatively-charged metal 136 
grid housed within the corneal applicator and a positively-charged 20G needle 137 
inserted through the sclera into the vitreous (figure 1A). The corneal applicator 138 
was vacuum-attached to the cornea. Once set-up, intra-ocular pressure was 139 
assessed manually by touch to ensure globe tension remained grossly 140 
normally. The reservoir was filled with differing riboflavin formulations (table 1) 141 
to above the level of the metal grid before beginning the iontophoresis 142 
treatment. Protocols varied either by iontophoresis dosage, soak time or 143 
riboflavin formulation and full parameters are given in table 2. Four globes 144 
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were studied for each protocol except for protocol F where n = 5. After the 145 
iontophoretic procedure, the applicator was removed and the corneas were 146 
rinsed with PBS to both remove any riboflavin on the corneal surface and to 147 
try to reduce riboflavin concentration within the epithelium. Corneas soaked 148 
for 30 minutes with 0.1 % w/v riboflavin in HPMC and saline (VibeX Rapid, 149 
Avedro, Inc) after epithelial debridement served as controls. 150 
 151 
Section preparation and imaging protocol 152 
We have previously described the use of TPF microscopy for imaging 153 
transepithelial riboflavin penetration.13,27 Briefly, following iontophoresis the 154 
globes were immediately immersed in liquid nitrogen. 35 µm corneal cross-155 
sections were cut on a cryostat 1 mm apart (including the central meridian) 156 
and then mounted on a slide and covered with fluorescence-free immersion 157 
oil (Immersol 518 F, Carl Zeiss Ltd.) to prevent any leakage of riboflavin out of 158 
the tissue. For lack of an appropriate oil-immersion objective, we placed a 159 
coverslip on top prior to imaging under a Leica 10x/0.3 NA water immersion 160 
objective. The time taken from the tissue thawing on the slide to image 161 
acquisition on the microscope was approximately 1 minute. This interval was 162 
kept as short as possible to minimize migration of fluorescein within the 163 
thawed tissue. A model-locked Ti:Sapphire laser, operating with a 140 164 
femtosecond pulse duration and 80 MHz pulse repetition rate, was used as 165 
the excitation laser source. TPF excitation light of 890 nm wavelength was 166 
chosen to correspond with the highest riboflavin absorption peak (445 nm) as 167 
determined by spectrophotometry.28 Emitted riboflavin fluorescence was 168 
collected in the backward (epi) configuration onto a de-scanned Leica HyD 169 
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detector with the pinhole opened to its maximum setting.  To avoid overlap 170 
with the absorption spectrum of riboflavin, fluorescence was detected in the 171 
range between 525 nm and 650 nm. (We previously investigated13 the 172 
presence of endogenous fluorescence within this spectral band by imaging 173 
negative controls without riboflavin and detected negligible TPF signal). 174 
 175 
Image analysis and concentration calibration 176 
Grey scale images were exported and analysed using Java-based imaging 177 
software (ImageJ, 1.48v, http:// imagej.nih.gov.ij; provided in the public 178 
domain by the National Institutes of Health, Bethesda, MD, USA). For each 179 
image, three separate 40-pixels wide rectangular regions of interest were 180 
manually selected (Figure 1B).  The intensity profiles with depth for each 181 
region of interest were then exported to a .txt file. The epithelial/stromal 182 
junction was then identified in each trace by the abrupt change in signal and 183 
confirmed with reference to the corresponding image of the region of interest. 184 
This information was used to align all three plots and a mean intensity plot 185 
was generated representing the average TPF signal for that image as a 186 
function of depth.  187 
 188 
In order to convert measured TFP signal into riboflavin concentration, we 189 
performed a calibration measurement. Each point on the calibration curve was 190 
produced by placing a known concentration of riboflavin solution on a well 191 
slide. The riboflavin solution was then covered with a layer of immersion oil 192 
and a coverslip in order to exactly replicate the measurement conditions used 193 
for imaging tissue. Image z-stacks were then acquired throughout the full 194 
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depth of the well slide using the same Leica 10x/0.3 NA water immersion 195 
objective as used for the tissue imaging. The resulting TPF signals are plotted 196 
as a function of depth in Figure 1C for selected riboflavin concentrations. As 197 
expected, the TPF signal is constant with depth. The average raw TPF signal 198 
measured at 60 µm below the riboflavin surface was then plotted against 199 
riboflavin concentration (Figure 1D). A quadratic equation was then fitted to 200 
the experimental data and the resulting curve was used to convert the TPF 201 
signal measured in corneal sections into riboflavin concentration. The TPF 202 
signal from a well slide reservoir of 0.1 % w/v riboflavin solution was acquired 203 
for every measurement session and the resulting data used to correct for 204 
drifts caused by variations in laser output power. 205 
 206 
 Mean (SD) concentrations were calculated from 4 globes tested for each 207 
protocol. Unpaired Student t-tests were used to compare riboflavin 208 
concentrations achieved at a depth of 300 µm. A p value less than 0.05 was 209 
considered significant. Analyses were performed in Excel for Mac, 2011; 210 
Microsoft Corp, Redmond, WA, USA).  211 
 212 
 213 
RESULTS 214 
 215 
Peak riboflavin concentration of 0.094 (± 0.002) % w/v was recorded in 216 
epithelium-off controls. At a depth of 300 µm corresponding to the 217 
demarcation line commonly observed after corneal cross-linking, the riboflavin 218 
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concentration was 0.082 (± 0.005) % w/v. Stromal riboflavin concentrations 219 
achieved through an intact epithelium with different iontophoresis protocols, 220 
along with corresponding color photograph and fluorescence microscopy 221 
images, are shown in figures 2-4 and summarised in table 3. Higher 222 
concentrations were achieved with longer iontophoretic dosage and longer 223 
solution contact (diffusion) time with the cornea. The best protocol (A), 224 
utilizing 0.25 % w/v riboflavin with BAC and two separate iontophoretic 225 
treatments followed by soak periods of 5 minutes to allow diffusion of 226 
riboflavin from the sub-epithelial tissues deeper into the stroma (the ‘St. 227 
Thomas’/Cardiff Iontophoresis protocol’, total time 20 minutes), was not 228 
significantly different with respect to stromal riboflavin concentrations 229 
compared with epithelium-off controls (0.082 [± 0.005] % w/v vs. 0.075 [± 230 
0.007] % w/v at a depth of 300 µm, p = 0.63, table 3). The best performing 231 
protocol (C) not containing BAC but with 0.25 % w/v riboflavin and the same 232 
iontophoresis treatments and soak times as protocol A, achieved a mean 233 
stromal concentration of 0.049 (± 0.008) % w/v at 300 µm (table 3). 234 
 235 
Near-uniform stromal riboflavin penetration with depth was observed in 236 
longer-duration protocols (A-C), as compared with shorter treatments in which 237 
the concentration fell by up to 40 % within the anterior 300 µm (protocols D-238 
F). Riboflavin solutions containing saline (protocols G, H), resulted in minimal 239 
stromal penetration (maximum 0.01 %). Of note, corneal thickness was 240 
observed to increase by approximately 50 µm following these saline-based 241 
iontophoretic applications. 242 
 243 
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The concentration of riboflavin within the epithelium was equivalent to or 244 
higher than that in the immediate underlying stroma. Extended rinsing of the 245 
surface effectively washed away any pre-corneal riboflavin film but did not 246 
selectively reduce the fluorophore load within the epithelium itself. A 5 minute 247 
corneal rinse after protocols A and B (MedioCross TE) resulted in a wash-out 248 
effect of both the epithelium and anterior stroma up to an approximate depth 249 
of 200 µm. 250 
 251 
  252 
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DISCUSSION 253 
 254 
In this study we have demonstrated that corneal stromal riboflavin penetration 255 
in iontophoretic transepithelial CXL can be improved by increasing soak time, 256 
solution concentration and iontophoretic dosage. 257 
 258 
The corneal epithelium has been previously shown to be a significant barrier 259 
to riboflavin penetration into the stroma.9,29,30 This has been confirmed by a 260 
series of experiments using spectrophotometry as an indirect measure of 261 
stromal riboflavin concentration. Using our TPF methodology, which can 262 
directly quantify riboflavin concentration through the entire depth of the 263 
corneal,13,28,31 we previously confirmed these findings, demonstrating very 264 
limited riboflavin diffusion through an intact epithelium with any of the several 265 
current commercially available transepithelial riboflavin formulations and 266 
protocols. 267 
 268 
Riboflavin is water soluble and negatively charged at physiological pH, and 269 
laboratory studies suggest that iontophoresis can be applied effectively to 270 
enhance riboflavin penetration in transepithelial CXL. Several groups have 271 
reported similar increases in corneal biomechanics19,22,23 in animal models as 272 
compared with epithelium-off CXL. Preliminary clinical studies have also been 273 
encouraging, with reported cessation of disease progression with up to 15 274 
month follow-up and improvements in keratometric and visual parameters.24–275 
26 However, the relative efficacy of this technique compared to epithelium-off 276 
CXL remains to be determined especially over longer term follow-up, and 277 
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current randomized prospective studies comparing the two techniques 278 
(clinicaltrials.gov.uk NCT02117999, NCT01868620, ISRCT 04451470) have 279 
yet to be reported. 280 
 281 
Existing recommendations for iontophoresis in transepithelial CXL utilize 1 mA 282 
for 5 minutes with a 0.1 % w/v riboflavin solution. Improved riboflavin 283 
penetration can be obtained by modifying these parameters. Stromal 284 
riboflavin concentrations using protocol A here were similar to epithelium-off 285 
controls (p = 0.63) (figure 4, table 3). This protocol utilized a solution of 0.25 286 
% w/v riboflavin with BAC and the ‘St. Thomas’/Cardiff Iontophoresis 287 
protocol’. This protocol was derived in collaborative pilot experimentation at St 288 
Thomas’ Hospital and Cardiff University using spectrophotometry, and 289 
comprises two cycles of iontophoresis each followed by a 5 minute soak 290 
period to allow time for riboflavin to diffuse more posteriorly. The use of the 291 
cationic surfactant BAC has been shown with percutaneous iontophoresis to 292 
have a synergistic effect on the transport of anions.22 We similarly observed 293 
this synergistic effect with higher stromal concentrations achieved with 294 
protocol A (0.25 % w/v riboflavin, BAC) compared to protocol C (0.25 % w/v 295 
riboflavin, no BAC) (figure 4, table 3). A further variable in iontophoresis 296 
relates to the zeta potential and electrophoretic mobility of different riboflavin 297 
solutions that may, in part, explain our results. Although beyond the scope of 298 
this study, this warrants further investigation in the future. 299 
 300 
A key advantage of our TPF imaging method, as compared to whole-tissue 301 
analysis (high-performance liquid chromatography, HPLC;19,32–34 302 
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spectrophotometry9,29,30) is the ability to quantify riboflavin concentration 303 
within the epithelium. We have previously demonstrated in transepithelial 304 
protocols (without rinsing the cornea) that epithelial riboflavin concentration 305 
often exceeds that in the underlying stroma.13 Analysing a full-thickness 306 
specimen, including a riboflavin-loaded epithelium and pre-corneal film, will 307 
lead to significant overestimation of corneal stromal riboflavin 308 
concentrations.13 Clinically, riboflavin loading in the epithelium may reduce 309 
CXL efficacy by attenuating UV light transmission to the stroma. It may also 310 
result in an ‘arc-eye’ type reaction, particularly where riboflavin preparations 311 
including BAC are used, accounting for the epithelial defects seen in up to 312 
two-thirds of patients after transepithelial CXL using Medio-Cross TE.35 The 313 
ideal transepithelial protocol would load the stroma with riboflavin, while 314 
leaving the epithelium relatively clear. To this end, in this study we rinsed the 315 
surface of the globe after iontophoresis in a bid to wash out some of the 316 
riboflavin from within the epithelium. Figures 3 and 4 and table 3 show that 317 
this approach did not work since there was no significant difference in 318 
fluorescence between the epithelium and the subjacent stroma. Extended 319 
rinsing (5 minutes) of the ocular surface in protocols A and B (MedioCross 320 
TE) also reduced corneal stromal concentrations of riboflavin up to an 321 
approximate depth of 200 µm. Stromal riboflavin elution was less evident with 322 
non-BAC containing solutions (protocols C and D), where the epithelial tight 323 
junctions were still probably largely intact. Although iontophoresis is not 324 
commercially promoted to be used with BAC-containing solutions, this stromal 325 
wash-out effect with prolonged rinsing of the ocular surface may compromise 326 
tissue cross-linking within the anterior cornea. 327 
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 328 
It is important to note that iontophoresis was ineffective with riboflavin 329 
formulations containing saline (Protocols G and H) that produced minimal 330 
riboflavin penetration and some stromal swelling.  331 
 332 
There are a number of limitations to this study. Firstly, results in ex-vivo rabbit 333 
corneas, although a better anatomical match to human corneal epithelial 334 
thickness than porcine eyes, may be affected by post-mortem changes in 335 
epithelial layer integrity. Despite steps to minimize this as described in the 336 
Methods section, some epithelial degradation and enhanced permeability is 337 
likely, and our results may overestimate stromal riboflavin absorption in 338 
clinical transepithelial CXL. Secondly, migration of riboflavin within the snap 339 
frozen tissue will have started as soon as the section thawed on the slide, 340 
resulting in an underestimation of stromal riboflavin concentrations. Finally, 341 
imaging through two media of different refractive indices (oil and water either 342 
side of the coverslip) may have increased optical aberrations as the laser light 343 
passes through. Any induced aberrations may have resulted in a small 344 
absolute loss of signal; but since this same method was employed for all 345 
imaged samples, no relative change in signal between samples should be 346 
present. Given these limitations, we are unable to guarantee an absolute 347 
concentration from this TPF data alone.  348 
 349 
In conclusion, this study confirms that transepithelial riboflavin penetration can 350 
be improved by increasing soak time, riboflavin concentration in the soak 351 
preparation and iontophoretic dosage. While the optimum tissue concentration 352 
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for effective CXL is unknown, Protocol C (0.25 % w/v riboflavin [BAC-free], St. 353 
Thomas’/Cardiff Iontophoresis protocol) achieves more than 50% greater 354 
stromal penetration compared to the standard iontophoresis protocol, as well 355 
as far higher concentrations than we have seen with non-iontophoresis 356 
transepithelial protocols.24 Although less than that achieved epithelium-off, its 357 
considerable stromal riboflavin penetration, without relying on epithelial-toxic 358 
additives, may represent the best transepithelial technique to date. Clinical 359 
trials will determine whether this level of stromal riboflavin penetration 360 
produces effective CXL.  361 
 362 
  363 
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Table 1 Riboflavin formulation 
 
Brand name (manufacturer) Composition 
Vibex Rapid (Avedro, Inc., Waltham, MA, USA) 0.1 % w/v riboflavin 5’-monophosphate, saline, HPMC 
Medio-Cross TE (Peschke Meditrade GmbH, Germany) 0.25 % w/v riboflavin 5’-monophosphate, HPMC, 0.01% benzalkonium 
chloride, disodium hydrogenphosphate, sodium dihydrogenphosphate, water 
*Ricrolin + 0.25% (Sooft Italia S.p.A. Montegiorgio, Italy) 0.25 % w/v riboflavin 5’-monophosphate, sodium edetate, trometamol, sodium 
dihydrogenphosphate dihydrate, sodium phosphate dibasic dehydrate 
Ricrolin + 0.1% (Sooft Italia S.p.A. Montegiorgio, Italy) 0.1 % w/v riboflavin 5’-monophosphate, sodium edetate, trometamol, sodium 
dihydrogenphosphate dihydrate, sodium phosphate dibasic dehydrate 
 
*Non-commercial formulation
 25
 
Table 2 Treatment protocols 
 
Protocol Solution Current dose I Soak I Current dose II Soak II Rinse
Control Vibex Rapid - 30 min - - -
A MedioCross TE 1mA 5 min 5 min 0.5 mA 5 min 5 min 5 min* 
B MedioCross TE 1mA 5 min 15 min - - 1 min 
C Ricrolin+ 0.25% 1mA 5 min 5 min 0.5 mA 5 min 5 min 5 min* 
D Ricrolin+ 0.25% 1mA 10 min - - - 5 min 
E MedioCross TE 1mA 5 min - - - 1 min 
F Ricrolin + 0.1% 1mA 5 min - - - 1 min† 
G Vibex Rapid 1mA 5 min - - - 1 min 
H Vibex Rapid 1mA 5 min 5 min 0.5 mA 5 min 5 min 5 min 
Min, minute; n = 4 for all protocols except F (n = 5), †previously published13 * St. Thomas’/Cardiff 
Iontophoresis protocol 
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Table 3 Corneal riboflavin concentrations 
Protocol Riboflavin concentration ± SD % w/v P value1 
 Epithelium Peak stroma 300 µm*  
Control - 0.094 ± 0.002 0.082 ± 0.005 - 
A 0.054 ± 0.004 0.078 ± 0.008 0.075 ± 0.007 0.63 
B 0.042 ± 0.006 0.054 ± 0.005 0.053 ± 0.005 0.016 
C 0.050 ± 0.008 0.057 ± 0.008 0.049 ± 0.008 0.001 
D 0.035 ± 0.004 0.039 ± 0.007 0.026 ± 0.003 < 0.001 
E 0.029 ± 0.003 0.029 ± 0.002 0.016 ± 0.003 < 0.001 
F 0.021 ± 0.002 0.018 ± 0.003 0.010 ± 0.001 < 0.001 
G 0.005 0.008 0.007 < 0.001 
H 0.005 0.006 0.005 < 0.001 
1Unpaired Student t-test comparing riboflavin concentration vs. control at a depth of 300 µm 
(depth chosen to correlate with demarcation zone commonly seen after corneal cross-linking). 
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FIGURE LEGENDS 455 
 456 
Figure 1 457 
(A) Iontophoresis riboflavin delivery system modified for use in ex-vivo eyes. 458 
The system comprised two electrodes: a negatively-charged metal grid 459 
housed within the corneal applicator and a positively-charged 20G needle 460 
inserted through the sclera into the vitreous. (B) Grey scale two-photon 461 
fluorescence image analysed in ImageJ with 3 box-plots (40 pixels wide) from 462 
which to average the signal in each section. The edges of the images were 463 
not analysed to avoid areas of vignetting. (C) TPF signals achieved with depth 464 
through diluted riboflavin solutions in a well slide. (D) Calibration curve used 465 
to calculate corneal riboflavin concentration from TPF signal. 466 
 467 
 468 
Figure 2  469 
Color photographic globe and section examples from each group tested 470 
allowing macroscopic comparative view of riboflavin penetration through the 471 
cornea into the anterior chamber. Upper row: Sagittal sections of treated 472 
globes mounted on a cryostat during section preparation. Lower row: 35 μm 473 
corneal sections prepared and laid on white paper for photographic contrast 474 
(visible shadows indicate section lifting off paper). A-H protocols as per table 475 
2. 476 
 477 
Figure 3 478 
Two-photon fluorescence images of tissue sections (grey scale). A-H 479 
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protocols as per table 2. e, epithelium; DM, Descemet’s membrane. All 480 
images have been formatted to increase brightness by the same amount to 481 
improve view. DM scroll artifact visible in some preparations. Apparent 482 
epithelial damage with BAC-containing protocol A should not be inferred as a 483 
treatment effect - our TPF methodology was not designed to qualify epithelial 484 
structural changes and a processing-induced artefact cannot ruled out.  485 
 486 
Figure 4 487 
Mean concentrations (standard deviation error bars) of riboflavin achieved 488 
using different transepithelial protocols, compared with epithelium-off 489 
penetration. Shaded area denotes epithelium. A-H protocols as per table 2. 490 
Note the increased concentrations achieved at 300um with protocols A and C 491 
compared to B and D due to the second iontophoresis/soak cycle. 492 
 493 
 494 




